Search research articles
Contact Us
Filters
Showing results (11-20 of 35) with videos related to
Page
of 4
Sort By:
Bone Marrow Transplantation
|
January 11, 2007
Cytogenetic evolution patterns in CML post-SCT
K Karrman, B Sallerfors, S Lenhoff, et al.
British Journal of Haematology
|
January 14, 1999
Clinical utility of immunoglobulin heavy chain gene rearrangement identification for tumour cell detection in multiple myeloma
A Swedin, S Lenhoff, T Olofsson, et al.
British Journal of Haematology
|
June 10, 2000
Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma
G Juliusson, F Celsing, I Turesson, et al.
European Journal of Haematology
|
June 26, 2001
Cost-utility analysis of high-dose melphalan with autologous blood stem cell support vs. melphalan plus prednisone in patients younger than 60 years with multiple myeloma
N Gulbrandsen, F Wisløff, E Nord, et al.
Annals of the Rheumatic Diseases
|
September 1, 1996
Transplantation with allogenic bone marrow from a donor with systemic lupus erythematosus (SLE): successful outcome in the recipient and induction of an SLE flare in the donor
G Sturfelt, S Lenhoff, B Sallerfors, et al.
European Journal of Haematology
|
January 1, 1996
NRAS mutations are rare in acute myeloid leukaemias with t(8;21) or inv(16)
I Panagopoulos, P Aman, B Johansson, et al.
Bone Marrow Transplantation
|
January 13, 2004
Autologous del(20q)-positive erythroid progenitor cells, re-emerging after DLI treatment of an MDS patient relapsing after allo-SCT, can provide a normal peripheral red blood cell count
J H Dykes, A Lindmark, S Lenhoff, et al.
European Journal of Haematology
|
September 13, 2002
Cytogenetic features of multiple myeloma: impact of gender, age, disease phase, culture time, and cytokine stimulation
T Nilsson, S Lenhoff, I Turesson, et al.
Cytotherapy
|
April 28, 2006
Quality assessment of autografting by probability evaluation: model estimation by clinical end-points in newly diagnosed multiple myeloma patients
O Roer, J Hammerstrøm, S Lenhoff, et al.
Bone Marrow Transplantation
|
October 4, 2016
Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation in Sweden, long-term results from all patients treated in 1994-2009
S Rosengren, U-H Mellqvist, H Nahi, et al.
Page
of 4
Search research articles
Search
Showing results (11-20 of 35) with videos related to
Sort By:
Page
of 4
Bone Marrow Transplantation
|
January 11, 2007
Cytogenetic evolution patterns in CML post-SCT
K Karrman, B Sallerfors, S Lenhoff, et al.
British Journal of Haematology
|
January 14, 1999
Clinical utility of immunoglobulin heavy chain gene rearrangement identification for tumour cell detection in multiple myeloma
A Swedin, S Lenhoff, T Olofsson, et al.
British Journal of Haematology
|
June 10, 2000
Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma
G Juliusson, F Celsing, I Turesson, et al.
European Journal of Haematology
|
June 26, 2001
Cost-utility analysis of high-dose melphalan with autologous blood stem cell support vs. melphalan plus prednisone in patients younger than 60 years with multiple myeloma
N Gulbrandsen, F Wisløff, E Nord, et al.
Annals of the Rheumatic Diseases
|
September 1, 1996
Transplantation with allogenic bone marrow from a donor with systemic lupus erythematosus (SLE): successful outcome in the recipient and induction of an SLE flare in the donor
G Sturfelt, S Lenhoff, B Sallerfors, et al.
European Journal of Haematology
|
January 1, 1996
NRAS mutations are rare in acute myeloid leukaemias with t(8;21) or inv(16)
I Panagopoulos, P Aman, B Johansson, et al.
Bone Marrow Transplantation
|
January 13, 2004
Autologous del(20q)-positive erythroid progenitor cells, re-emerging after DLI treatment of an MDS patient relapsing after allo-SCT, can provide a normal peripheral red blood cell count
J H Dykes, A Lindmark, S Lenhoff, et al.
European Journal of Haematology
|
September 13, 2002
Cytogenetic features of multiple myeloma: impact of gender, age, disease phase, culture time, and cytokine stimulation
T Nilsson, S Lenhoff, I Turesson, et al.
Cytotherapy
|
April 28, 2006
Quality assessment of autografting by probability evaluation: model estimation by clinical end-points in newly diagnosed multiple myeloma patients
O Roer, J Hammerstrøm, S Lenhoff, et al.
Bone Marrow Transplantation
|
October 4, 2016
Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation in Sweden, long-term results from all patients treated in 1994-2009
S Rosengren, U-H Mellqvist, H Nahi, et al.
Page
of 4